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Outline
This thesis described several studies on the use of stimulant medication among children in 
the Netherlands using qualitative as well as quantitative methods and parents, physicians, 
and pharmacy data as data sources. In this closing chapter the main results will be 
summarized and all results will be taken into consideration to answer and discuss the 
following four research questions raised in the introduction:
1)  Is concern about stimulant use among children justified for the Dutch situation? 
2)  Is stimulant medication part of a multimodal treatment program?  
3)  What is the use of psychotropic co-medication among stimulant users? 
4)  Are pharmacy data useful in child psychiatry research? 
Finally, I will reflect on recent developments in the field of ADHD treatment and give 
recommendations for future research. 
Summary
In the first chapters of this thesis (chapter 2-5) several aspects of current practice of 
stimulant treatment among children in the Netherlands were described. Chapter 2 described 
how pharmacies were used to recruit parents of stimulant-treated children for a 
questionnaire survey and how the prescribing physician was approached. Also, response 
and consent rates were analyzed with respect to characteristics of the stimulant-treated 
children and physicians. We found that the community pharmacy can be a valuable starting 
point for recruiting parents and physicians of users of prescription drugs for survey research, 
yielding high response rates and low consent refusal rates.
 From the questionnaire survey held among parents of stimulant-treated children we 
described the current practices around the initiation and follow-up care of stimulant 
treatment among children (chapter 3). We found that 91% of the stimulant-treated children 
were diagnosed with ADHD. In 77% of the cases the child or the parents received non-
pharmacological therapy besides stimulants. One out of five children received psychotropic 
co-medication; melatonin (11%) and antipsychotics (7%) were mentioned most frequently.
Stimulant treatment was initiated by child psychiatrists and pediatricians in 51% respectively 
32% of the cases, but GPs provided the repeat prescriptions for 61% of the children. Almost 
20% of the children did not receive follow-up care concerning the treatment with stimulants. 
The odds of not receiving follow-up care was increased when the prescribing responsibility 
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was transferred between physicians, mostly from specialist to GP. Children who visited 
pediatricians for follow-up were more likely to undergo physical examinations than children 
who visited child psychiatrists and GPs. From the results of this survey we concluded that 
major concern about the injudicious initiation of stimulant treatment by GPs appears 
unnecessary for the Dutch situation. However, our study did demonstrate cause for concern 
about the follow-up care for stimulant-treated children.
 There has been increasing awareness that ADHD is often accompanied with other 
psychiatric disorders that warrant special consideration in the treatment. Therefore, we 
investigated whether the presence of psychiatric co-morbidity in stimulant-treated children 
with ADHD was associated with the use of psychotropic co-medication and receiving non-
pharmacological treatment, using data from the survey among stimulant-prescribing 
physicians (chapter 4). Among the stimulant-treated children diagnosed with ADHD, 
pervasive developmental disorder (PDD) and oppositional defiant disorder/conduct disorder 
(ODD/CD) were the most frequently reported co-morbid psychiatric disorders (both 10%). 
We found statistical significant associations between the presence of co-morbidity and the 
use of antipsychotics and the use of melatonin. Antipsychotics were, with 17%, most 
frequently used among stimulant-treated children with ADHD and co-morbid PDD. Melatonin 
was mainly used among children with co-morbid ODD/CD (16%). The presence of 
psychiatric co-morbidity was also associated with higher use of non-pharmacological 
treatment. In the ADHD-only group 74% of the children or their parents received or had 
received any non-pharmacological treatment. This percentage was 92% for ADHD and co-
morbid PDD, 90% for ADHD and co-morbid ODD/CD and 82% for children with ADHD and 
other co-morbidity. Children with co-morbid PDD or ODD/CD received more intensive 
behavioral interventions and day treatment than the other children and were more often 
treated in an inpatient clinic. Also counseling was most frequently offered to parents of 
children with ADHD and co-morbid PDD or ODD/CD. Home-based interventions were 
especially applied when co-morbid PDD was present, as it was provided in 23% of these 
families, and in no more than 10% of the other families. We concluded that stimulant-treated 
children with ADHD and psychiatric co-morbidity received more psychotropic co-medication 
and non-pharmacological treatment than children with ADHD-only. Moreover, the type of 
psychotropic co-medication and non-pharmacological treatment received by the children and 
the parents, depended on the specific co-morbid psychiatric disorder being present.  
 The chronic course of ADHD and the pharmacokinetic parameters of short-acting 
stimulants make the double-blind, placebo-controlled, randomized N-of-1 trial very suitable 
for assessing the effectiveness of stimulants in individual patients. In chapter 5 we examined 
the use of N-of-1 trials among children in the Netherlands when starting stimulant treatment. 
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First, we interviewed physicians about their N-of-1 protocols. Physicians mentioned 
assessing individuals’ response and dose-finding to be their main purposes for using N-of-1 
trials. None of the physicians’ protocols was the same with regard to trial length, dosing 
schedule and evaluation of the trial. Second, we estimated the use of N-of-1 trials with 
stimulants in a large pharmacy record database. The annual percentage of children starting 
stimulant treatment with an N-of-1 trial, fluctuated between 0.6% (3/462) and 3.3% (10/301) 
from 2000-2004. We could not detect a statistical significant difference between the 
continuation of stimulant treatment after start with and without an N-of-1 trial. We concluded 
that N-of-1 trials with stimulants are infrequently and not optimally used in the Netherlands.
 Chapter 6 and 7 were dedicated to research on co-medication using a large pharmacy 
record database. The use of psychotropic co-medication among stimulant-treated children in 
the Netherlands from 1998 to 2002 is examined in chapter 6. The prevalence of stimulant 
use among children had increased from 0.6% in 1998 to 1.2% in 2002. The incidence 
appeared to have stabilized since 2000 around 0.27%. We found that among stimulant-
treated children, the use of psychotropic co-medication had increased from 12% in 1998 to 
almost 15% in 2002. The most frequently used co-medications were antipsychotics, with 8% 
in 2002. The use of antidepressants and melatonin had increased slightly, though 
significantly, from both less than 0.2% in 1998 to 1.8% respectively 1.5% in 2002.
 Comparing the use of co-medication with figures from other countries was complicated 
due to differences in timing of the study period. Comparison was further aggravated by the 
variety of terms used for co-medication, and the lack of information on how co-medication 
was exactly operationalized. Therefore, in chapter 7 we examined the impact of different 
definitions for co-medication on the reported proportion of patients having co-medication 
using pharmacy data. We demonstrated that different co-medication patterns, varying in 
time window and criteria for overlap, yielded clinical as well as statistical significant different 
estimates. Uniformity in terminology of co-medication is crucial for a clear communication 
between clinicians and researchers. We therefore proposed to distinguish the following 
patterns when studying co-medication: ‘co-prescribing’, ‘concomitant medication’ and 
‘possibly concurrent medication’. The research question should determine the co-medication 
pattern of interest. The medication and disease under study and possible safety aspects are 
important to determine the time window. 
 Chapter 8 touched upon the economical aspects of stimulant treatment. ADHD places a 
substantial economic burden on patients, families and society and it has been suggested 
that the full costs associated with the treatment of ADHD may be reduced by (more 
expensive) once-daily dosing regimens. In chapter 8 we investigated the cost-effectiveness 
of treatment with long-acting methylphenidate-OROS for children with ADHD for whom 
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treatment with immediate-release (IR) methylphenidate is suboptimal. The incremental cost-
effectiveness ratio (ICER) of methylphenidate-OROS treatment compared to IR-
methylphenidate was estimated at 2,004 euros per quality adjusted life year. The ICER was 
sensitive to changes in resource use and the probability of stopping stimulant treatment. 
From our study methylphenidate-OROS appeared a cost-effective treatment option for this 
subgroup of children with ADHD. 
Discussion
In the following part of this chapter I will discuss the four research questions raised in the 
introduction, reflect on recent developments in the field of ADHD treatment and give 
recommendations for future research. 
1) Is concern about stimulant use among children justified for the Dutch situation? 
Based on the presented data we can not conclude whether stimulants are under or 
overprescribed for children in the Netherlands. With an estimated prevalence of ADHD of 3-
5% [1] and assuming that a conservative half of the children with ADHD could benefit from 
treatment with stimulants, a prevalence of 1.5 – 3.0% of stimulant use could be expected. 
We found a lower prevalence of 1.2% in 2002 among 0-19-year-olds (chapter 6). In a study 
from the USA the authors suggested that many children with ADHD are still undiagnosed 
and untreated, whereas on the other hand children treated with stimulants do not meet the 
full diagnostic criteria for ADHD [2]. This suggestion might probably also be valid for the 
Dutch situation. The prevalence of stimulant use in the Netherlands is not as high as in the 
USA with 2.9% in 2002 [3]. In Europe, however, the Netherlands is one of the countries with 
the highest stimulant consumption rate together with the United Kingdom, Belgium, 
Germany, Iceland and Switzerland [4].
 We found that for the vast majority of stimulant-treated children in the Netherlands, 
stimulant treatment was initiated by specialists, in particular child psychiatrists. According to 
the parents of stimulant-treated children, they received the first prescription for stimulant 
medication from the physician after on average four visits [5]. Although we had no 
information on how the child was assessed and we could not pass judgment on the 
appropriateness of the diagnosis, according to the parents and physicians almost all children 
received stimulant medication for ADHD, the indication for which these drugs are approved. 
Taking all these results into consideration, we think that major concern about injudicious 
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initiation of stimulant treatment appears unnecessary for the Dutch situation. However, 
follow-up care for stimulant-treated children appeared to be noticeably inadequate.
Follow-up
Because ADHD affects children over many years and long-term treatment is often indicated, 
carefully monitoring of the child’s development is very important, as is recommended in most 
ADHD guidelines [6-9]. The importance of regular monitoring is also supported by findings of 
the Multimodal Treatment Study of Children with ADHD (MTA) that showed the medication 
management condition to be superior to ‘treatment as usual’ (community care group), even 
though two-third of the children in this latter group also received stimulant medication [10]. 
This reveals the importance of the procedures in the medication management protocol in its 
entirety, including monthly supportive contacts and treatment adjustments.
 Considering the MTA-findings, follow-up care for stimulant-treated children in the 
Netherlands appeared far from optimal, because for one out of five stimulant-treated 
children no follow-up visit was scheduled. We found that transfer and sharing of prescribing 
responsibility increased the risk of not being monitored. In two third of the stimulant-treated 
children GPs were involved in prescribing of repeat prescriptions, and therefore it is 
important to clarify their role in follow up care. It is our view that GPs might take over 
prescribing responsibility after the initiation phase and perform physical monitoring, but only 
after additional training and in close liaison with the treating specialist. However, the 
specialist should remain responsible for monitoring the course of ADHD in these children. 
This is in concordance with the recommendations in the recently published Dutch 
multidisciplinary ADHD guideline [9]. Apparently careful monitoring is not yet a matter of 
course, and therefore it is important to develop a clear en comprehensive monitoring system 
for stimulant-treated children, in which it is only possible to continue stimulant prescribing 
with periodic monitoring visits. 
 During follow-up, rating scales for evaluating the effectiveness of treatment were 
infrequently used and the thoroughness of the physical monitoring depended on the type of 
physician visited (chapter 3). There should be more uniformity in the physical examinations 
undertaken during follow-up, and this ought to be independent of the type of physician 
visited. With respect to physical examinations the Dutch guideline is clear and recommends 
to measure body weight and length annually and to measure the child’s blood pressure and 
heart rate before the start of treatment and once the treatment has stabilized [9]. Periodic 
electrocardiographic (ECG) monitoring is not indicated according to this guideline, which is 




Another worrisome aspect of stimulant treatment is inadequate dosing. In the Netherlands 
the mean prescribed daily dose for methylphenidate was approximately 25 mg (chapter 6). 
Comparing this with the MTA study, this is 13 mg lower than the mean dose in the 
medication management condition, and 6 mg lower than the mean dose in the medication 
management condition when combined with behavioral therapy [10]. In addition, in the MTA 
study children received their medication on a three-times-daily regimen, while in the 
Netherlands more than half of the children took their stimulant medication in two or less 
doses per day [5]. For clinical practice these MTA findings imply that careful dose-titration at 
the start of treatment, three-times-daily administration and regular medication monitoring 
visits may provide substantial benefits for treatment outcome. The new Dutch ADHD 
guidelines already incorporated these MTA findings [9]. The guideline also acknowledges 
the additional value of the N-of-1 method for dose-finding, but points out that for practical 
reasons the N-of-1 method may not always be feasible. Yet whatever approach for dose-
finding is chosen, the critical element is to do it in a systematic way [12].
2) Is stimulant medication part of a multimodal treatment program?
For three-quarter of the children in our questionnaire study, stimulant treatment was or had 
been combined with a form of non-pharmacological treatment for the child or parents. Non-
pharmacological treatment was defined broadly, including e.g. intensive training, parent 
training and home training, physiotherapy and diet. Children with ADHD and co-morbid 
psychiatric disorders received considerable more treatment modalities than children with an 
ADHD diagnosis only, in particular children with co-morbid PDD and ODD/CD. Thus, in the 
Netherlands the majority of the stimulant-treated children and their families received 
multimodal treatment. It should be noted that no judgment could be made about the 
appropriateness of therapies and no distinction was made between continuous and 
temporary therapies. 
 Although all guidelines for the treatment of ADHD recommend a multimodal treatment 
program, the additional value of combined treatment over medication alone is controversial 
[13]. To date, there are only a few sound studies that compared the effect of combination 
treatment with either medication or behavioral therapy alone, and these studies gave 
conflicting results [10,14,15]. The conclusions from the large MTA trial that for core ADHD 
symptoms no advantage was found of combination therapy to medication management 
alone are still under debate [10]. A clear advantage of combination treatment was found 
after alternative outcome analyses of the MTA-trial data on the individual level [16] and 
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using composite outcome measures [17]. Until more studies on the effectiveness of 
combination treatment and medication alone become available, a multimodal approach 
tailored to the child and family has the best likelihood to manage the symptoms of ADHD 
and that of its co-morbid disorders. Addition of behavioral interventions may be of help when 
medication has worn off or cannot be taken. The overall treatment will need to be of high-
quality and sustained over a long period, resulting in the highest possible quality of life and 
developmental level for the child. 
3) What is the use of psychotropic co-medication among stimulant users? 
In this thesis we considered psychotropic co-medication as the use of other psychotropic 
agents (i.e. antidepressants, antipsychotics, anticonvulsants, lithium, clonidine, hypnotics, 
anxiolytics and melatonin) besides the use of stimulants. The use of psychotropic co-
medication among stimulant-treated children has increased in the Netherlands over the 
years (chapter 6), but the increase was not as large as reported from the USA [18-20]. 
Although the vast majority of the Dutch stimulant users received stimulants as monotherapy, 
nearly one out of five children received psychotropic drugs besides stimulant medication in 
2003.
 By combining stimulants with other psychotropic drugs clinicians aim to enhance 
response in partial responders to monotherapy [21], treat co-morbid disorders or adverse 
effects [22] or potentiate the efficacy of response to antidepressants [23]. However, 
combining medication may also bring about potential problems, such as drug interactions, 
adverse reactions and difficulties in assessing the contribution of each drug to the overall 
effect [24,25]. With respect to stimulant medication there is still a lack of data supporting the 
effectiveness and safety of the addition of other psychotropic drugs [22].
 In contrast to stimulants most other psychotropic medications are not thoroughly 
studied for the treatment of childhood psychiatric disorders and most of the time not even 
approved for the use in children. The safety of psychotropic drugs among children have 
received a lot of attention recently. The ‘off-label’ use of the atypical antipsychotics is 
substantial and has increased in recent years [20,26], and their risks for weight gain and 
metabolic disorders was lively discussed in the lay media [27,28]. In our survey, parents 
reported that nearly one out of thirteen children used an antipsychotic besides their stimulant 
treatment (chapter 3), a figure that later was affirmed by a study using pharmacy data 
(chapter 6). The use of antipsychotics was mainly restricted to children with ADHD and co-
morbid psychiatric disorders, especially pervasive developmental disorder (chapter 4). We 
assume that antipsychotics were not used to treat core ADHD symptoms but more to treat 
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symptoms of the co-morbid disorder (e.g. aggressive behavior), although we have no data to 
support this. Also antidepressants, especially SSRIs, have received a lot of negative 
attention worldwide due to the increased risk of suicidal thinking and behavior in children 
and adolescents with major depression and other psychiatric disorders [29,30]. Although the 
use of SSRIs among stimulant-treated children in the Netherlands has increased to 1.8% in 
2002 (chapter 6), the use is not as high as the 4.3% reported from the USA [20]. It would be 
interesting to see whether the negative publicity and the recommendations against the use 
of SSRIs among children has influenced the course of SSRI use as monotherapy but also as 
co-medication among stimulant users. 
 We were surprised that parents reported one out of nine children used melatonin for co-
medication. Melatonin is not approved as a drug in the Netherlands and research shows 
conflicting results about the effectiveness of melatonin for sleep disorders [31,32]. 
Remarkable were also the regional differences in melatonin prescribing, ranging from 5- 
26% per ZIP-region (data not shown in thesis). Although no alarming side effects have been 
reported yet, more systematic research and long-term research has to be done to be 
conclusive on the effectiveness and safety of melatonin in children.
 When the use of other psychotropic drugs together with stimulants is considered, 
before addition of a second psychotropic drug, first the stimulant dose should be optimally 
titrated and the effect of stimulants should be carefully examined. Safer et al. recommend to 
use the N-of-1 method for complex combinations of psychotropic medications to produce a 
systematic and more objective assessment of the contributions of each drug to the overall 
effect and possible side effects [22]. However, for most psychotropic medications an N-of-1 
trial will be inappropriate, because of their delayed onset and termination of action, causing 
carry-over effects. 
4) Are pharmacy data useful in child psychiatry research? 
In all studies described in this thesis the community pharmacy was in some way involved; 1) 
as a data source for drug utilization studies or 2) as the starting point for the recruitment of 
users of prescription drugs (or their parents).
Drug utilization studies  
Previous studies have demonstrated that pharmacy data from Dutch community pharmacies 
can be a reliable source of information regarding the use of prescription drugs [33,34]. All 
prescriptions from general practitioners (GPs) and specialists are dispensed in community 
pharmacies and due to a high patient-pharmacy allegiance in the Netherlands and 
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sophisticated and standardized pharmacy software, medication records for each patient are 
virtually complete [35]. Unfortunately, this completeness might be jeopardized, now that new 
competitors such as internet pharmacy and outpatient clinic pharmacies have entered the 
pharmacy retail market.
 A limitation of pharmacy data is the absence of clinical information such as the 
diagnosis, the indication for prescribing medication, the medical history and other features of 
the patient. For more in-depth clinical research on medication use other data sources should 
be addressed in addition. To study the current practices of stimulant treatment in the 
Netherlands, we therefore obtained more specific data on diagnosis and stimulant treatment 
from parents of stimulant-treated children and their prescribing physician. Another limitation 
of pharmacy data is the absence of medication used during hospital stay, supplied by 
dispensing GPs and the incomplete information on over-the counter (OTC) medication, 
possibly leading to an underestimation of medication use. This is illustrated by the different 
percentages of melatonin use among stimulant-treated children: 1.5% in 2002 according to 
pharmacy data (chapter 6) compared to about 7% according to survey among parents of 
stimulant-treated children in the same regions (chapter 3, regional data not presented). 
Recruitment  
We used community pharmacies as a starting point to detect stimulant-treated children in 
their computer system and to function as intermediaries between us researchers and the 
parents. By using this pharmacy-based recruiting method, stimulant-treated children were 
selected from the general pediatric population, irrespective of the prescribing physician and 
without influencing current practice. Recruitment of parents via for example a child 
psychiatry or pediatric clinic would have led to substantial selection bias. However, Knoester 
et al. showed pharmacy-based recruitment is also not without selection bias [36]. They 
demonstrated that their pharmacy-based recruitment procedure lead to selection bias 
because community pharmacists unintentionally applied selection criteria before 
approaching their patients for research. Although we provided a very strict recruitment 
protocol to the participating pharmacists, we can not completely rule out that our 
pharmacists also added their own selection criteria before sending out the questionnaires. 
Knoester et al. found that consent was less often obtained among patients with a higher 
burden of disease, among people living in highly urbanized regions, and among patients 
using drugs that could be considered as markers for off-label use of the drug of interest. 
Unfortunately, we had no information on the non-responding parents and their children, 
hindering a non-response analysis on this level. Information about these non-responders 
would have refined the interpretation of our results. However, although not completely 
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without selection bias, we think that for child psychiatry research, pharmacy data and 
pharmacy based recruitment procedures can a valuable, additional tool for studying drug-
related issues. 
Developments and recommendations for future research 
Since the start of the research presented in this thesis four years ago, a lot of developments 
have taken place with respect to the treatment of ADHD.
ADHD guideline 
In October 2005, the new Dutch guideline for diagnostics and treatment of ADHD in children 
and adolescents [9] replaced the old guideline from 1999 published by the Dutch Psychiatric 
Association [37]. In contrast to the latter, the new guideline was developed by a 
multidisciplinary group representing the various relevant professional associations and 
patient organizations. This integrated approach is important because different health care 
providers and professionals should be involved in detecting, diagnosing and treatment of 
ADHD. In some regions in the Netherlands the use of a multidisciplinary ADHD team has 
already proven to be successful [38]. It would be interesting to see whether this approach is 
adopted by other regions as well. Every effort should be made to effectively implement the 
new ADHD guideline, in order to guarantee that children and their parents in different 
regions of the country can expect the same standard of care.
New formulations and drugs 
Over the past years, new drugs and formulations for the treatment of ADHD have been 
developed. In the Netherlands two new compounds have been approved for the treatment of 
ADHD since the end of 2002: methylphenidate-OROS (Concerta®) and atomoxetine 
(Strattera®). Methylphenidate-OROS is a long-acting, once-daily formulation with 
methylphenidate. In clinical trials methylphenidate-OROS has been shown to be as effective 
as three-times-daily immediate release methylphenidate with a similar safety pattern [39]. An 
advantage of this once-daily formulation is the possibility to simplify the dosing schedule and 
eliminating the need for in-school administration. In addition, in contrast to immediate 
release methylphenidate, the methylphenidate-OROS tablet is difficult to crush and its 
methylphenidate content can not easily be extracted, making it a formulation with a lower 
abuse potential [40].
 Atomoxetine is the first non-stimulant approved for the treatment of ADHD in children 
and is also dosed once per day. The precise mechanism by which atomoxetine produces its 
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therapeutic effects in ADHD is unknown, but it is thought to be related to selective inhibition 
of the pre-synaptic norepinephrine transporter. The efficacy of atomoxetine in children with 
ADHD has been demonstrated in several clinical trials [41-43], but direct comparison studies 
with methylphenidate are still lacking. Clinical trials demonstrated that atomoxetine is 
generally thought to be safe and well-tolerated. However, in September 2005, health care 
professionals were alerted that children and adolescents taking atomoxetine prescribed for 
ADHD should be closely monitored for changes in behavior after a meta-analysis showed a 
small but statistically significant increase (0.4% vs. 0%) in suicidal thinking in children taking 
atomoxetine compared to placebo [44].
 In the Netherlands, methylphenidate-OROS and atomoxetine are not available for all 
ADHD patients as for both once-daily formulations co-payments up to 97 euros per month 
are required [45]. In the Dutch Price Reference System (GVS) both drugs are clustered with 
immediate-release (IR) methylphenidate on GVS-list 1a. This entails a controlled 
reimbursement limit at the price of IR-methylphenidate, which is 16 to 30% of the price of 
methylphenidate OROS and atomoxetine. According to the advisory council of the Health 
Care Insurance Board, there is no evidence that methylphenidate-OROS and atomoxetine 
are different from IR-methylphenidate with respect to efficacy and safety, and therefore both 
drugs were not assigned to the GVS-list 1b, entailing liberal price setting. The current 
reimbursement status of methylphenidate-OROS and atomoxetine, received a lot of criticism 
from patients’ associations, parents, physicians and teachers [46-49]. We found that in 2005 
in the north-eastern part of the Netherlands, 18% of stimulants users younger than 20 years 
received a prescription for methylphenidate-OROS [InterAction database, data not shown]. 
This illustrates that a considerable number of parents prefer once-daily methylphenidate-
OROS over IR-methylphenidate, despite the extra costs. Since the introduction of the new 
health care insurance system in the Netherlands in January 2006, it has become possible 
for patients to pay for an additional non-compulsory insurance, that includes reimbursement 
of full costs for all prescription drugs.
 In the cost-effectiveness analysis presented in chapter 8 in this thesis, 
methylphenidate-OROS showed to be a cost-effective treatment for ADHD children for 
whom treatment with IR-methylphenidate is suboptimal. In this analysis no account was 
taken of direct medical costs associated with e.g. in-school administration of IR-
methylphenidate or indirect costs of suboptimal treatment such as parental work-loss 
because data were lacking. To refine cost-effectiveness analyses on ADHD treatment, 
future research should endeavor to quantify these direct non-medical and indirect costs 




Although stimulant medications have been used for over 60 years and are one of the most 
extensively studied medications in children and adolescents, still long-term effects and 
safety of stimulant treatment have not been well established [50]. Recently in the USA, the 
discussion about the safety of stimulant use flared up after an advisory committee of the 
Food and Drug Administration unexpectedly recommended to display a ‘black box’ warning 
label on stimulants, clearly indicating the cardiovascular risks of stimulant drugs [51,52]. This 
recommendation was not based on new evidence about the cardiovascular risk of 
stimulants, but was mainly driven by worries that stimulants are being overused in the USA 
and about the sharp increases in the number of especially stimulant-treated adults. 
According to the American Heart Association the changes in blood pressure and pulse 
under the influence of stimulants are clinically insignificant [11] and at the end of March 
2006, an FDA’s pediatric advisory committee recommended against the ‘black box’ warning 
but did recommend adding more clear information to the label [53]. Probably, the discussion 
about the safety of stimulants will continue, but for now stimulants, with all their risks and 
benefits, remain the gold standard against which all other ADHD medications are compared.
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